PL1802658T3 - Chimeryczne i humanizowane przeciwciała monoklonalne przeciw interleukinie-13 - Google Patents
Chimeryczne i humanizowane przeciwciała monoklonalne przeciw interleukinie-13Info
- Publication number
- PL1802658T3 PL1802658T3 PL05757024T PL05757024T PL1802658T3 PL 1802658 T3 PL1802658 T3 PL 1802658T3 PL 05757024 T PL05757024 T PL 05757024T PL 05757024 T PL05757024 T PL 05757024T PL 1802658 T3 PL1802658 T3 PL 1802658T3
- Authority
- PL
- Poland
- Prior art keywords
- chimeric
- monoclonal antibodies
- antibodies against
- against interleukin
- humanised monoclonal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0414799.7A GB0414799D0 (en) | 2004-07-01 | 2004-07-01 | Immunoglobulins |
GB0423675A GB0423675D0 (en) | 2004-10-25 | 2004-10-25 | Immunoglobulins |
PCT/GB2005/002581 WO2006003407A2 (en) | 2004-07-01 | 2005-06-30 | Chimeric and humanised monoclonal antibodies against inteleukin- 13 |
EP05757024A EP1802658B1 (en) | 2004-07-01 | 2005-06-30 | Chimeric and humanised monoclonal antibodies against interleukin-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL1802658T3 true PL1802658T3 (pl) | 2012-04-30 |
Family
ID=35521159
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL05757024T PL1802658T3 (pl) | 2004-07-01 | 2005-06-30 | Chimeryczne i humanizowane przeciwciała monoklonalne przeciw interleukinie-13 |
Country Status (26)
Country | Link |
---|---|
US (2) | US7807788B2 (pl) |
EP (2) | EP2436697B1 (pl) |
JP (1) | JP5102616B2 (pl) |
KR (1) | KR20070034609A (pl) |
AR (1) | AR049565A1 (pl) |
AT (1) | ATE535545T1 (pl) |
AU (1) | AU2005259025B2 (pl) |
BR (1) | BRPI0512826A (pl) |
CA (1) | CA2571799A1 (pl) |
CY (1) | CY1112372T1 (pl) |
DK (1) | DK1802658T3 (pl) |
ES (2) | ES2378173T3 (pl) |
HR (1) | HRP20120139T1 (pl) |
IL (1) | IL180152A0 (pl) |
MA (1) | MA28726B1 (pl) |
MX (1) | MX2007000026A (pl) |
NO (1) | NO20070189L (pl) |
NZ (1) | NZ552063A (pl) |
PE (1) | PE20060376A1 (pl) |
PL (1) | PL1802658T3 (pl) |
PT (1) | PT1802658E (pl) |
RU (1) | RU2404192C2 (pl) |
SG (1) | SG153878A1 (pl) |
SI (1) | SI1802658T1 (pl) |
TW (1) | TWI307630B (pl) |
WO (1) | WO2006003407A2 (pl) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0407315D0 (en) | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
KR101073590B1 (ko) * | 2003-07-15 | 2011-10-14 | 메디뮨 리미티드 | Il-13에 대한 인간 항체 분자 |
PT2805728T (pt) * | 2003-12-23 | 2020-04-08 | Genentech Inc | Novos anticorpos anti-il13 e o uso dos mesmos |
AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
US9072716B2 (en) | 2005-04-15 | 2015-07-07 | The United States of America, as represented by the Secretary Department of Health by Human Servies | Methods of treating and preventing inflammatory bowel disease involving IL-13 and NKT cells |
CA2623429C (en) | 2005-09-30 | 2015-01-13 | Medimmune Limited | Interleukin-13 antibody composition |
EP2532679B1 (en) | 2005-10-21 | 2017-04-12 | Novartis AG | Human antibodies against il13 and therapeutic uses |
GB0600488D0 (en) * | 2006-01-11 | 2006-02-22 | Glaxo Group Ltd | Immunoglobulins |
TW200740843A (en) * | 2006-01-24 | 2007-11-01 | Domantis Ltd | Ligands that bind IL-4 and/or IL-13 |
ES2817756T3 (es) | 2006-09-08 | 2021-04-08 | Abbvie Bahamas Ltd | Proteínas de unión a interleuquina-13 |
PL2069403T3 (pl) * | 2006-10-02 | 2015-08-31 | Regeneron Pharma | Przeciwciała ludzkie o wysokim powinowactwie wobec receptora ludzkiej IL-4 |
DE102008053503B4 (de) * | 2008-10-28 | 2011-04-28 | Justus-Liebig-Universität Giessen | Immunologischer Test zum Nachweis von Autoantikörpern gegen testikuläre Antigene |
GB0904214D0 (en) | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
US20100303821A1 (en) * | 2009-05-28 | 2010-12-02 | Glaxo Group Limited | Immunoglobulins |
ES2813398T3 (es) * | 2009-10-20 | 2021-03-23 | Abbvie Inc | Aislamiento y purificación de anticuerpos anti-IL-13 usando cromatografía de afinidad a Proteína A |
US20130202639A1 (en) * | 2010-03-25 | 2013-08-08 | Konstantin G. Kousoulas | Synthetic Herpes Simplex Viruses for Treatment of Cancers |
NZ609493A (en) | 2010-12-16 | 2015-11-27 | Genentech Inc | Diagnosis and treatments relating to th2 inhibition |
AU2013305945B2 (en) | 2012-08-21 | 2018-07-26 | Regeneron Pharmaceuticals Inc. | Methods for treating or preventing asthma by administering an IL-4R antagonist |
TWI679019B (zh) * | 2013-04-29 | 2019-12-11 | 法商賽諾菲公司 | 抗il-4/抗il-13之雙特異性抗體調配物 |
TWI755763B (zh) | 2013-06-04 | 2022-02-21 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
TWI634900B (zh) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法 |
CA3174012A1 (en) | 2013-09-13 | 2015-03-19 | Genentech, Inc. | Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products |
KR102571391B1 (ko) | 2013-09-13 | 2023-08-29 | 제넨테크, 인크. | 정제된 재조합 폴리펩티드를 포함하는 방법 및 조성물 |
SG11201603127WA (en) | 2013-10-23 | 2016-05-30 | Genentech Inc | Methods of diagnosing and treating eosinophilic disorders |
SG10201806729VA (en) | 2014-02-07 | 2018-09-27 | Medimmune Llc | Novel assay to detect human periostin |
JP2017507939A (ja) | 2014-02-21 | 2017-03-23 | ジェネンテック, インコーポレイテッド | 抗il−13/il−17二重特異性抗体及びその使用 |
KR20220070544A (ko) | 2014-02-28 | 2022-05-31 | 리제너론 파아마슈티컬스, 인크. | Il-4r 길항제의 투여에 의한 피부 감염의 치료 방법 |
CA2943326A1 (en) | 2014-04-11 | 2015-10-15 | Novartis Ag | Methods of selectively treating asthma using il-13 antagonists |
EP3218412A1 (en) | 2014-11-14 | 2017-09-20 | Sanofi Biotechnology | Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist |
CN107430117A (zh) | 2015-03-16 | 2017-12-01 | 豪夫迈·罗氏有限公司 | 检测和定量IL‑13的方法和在诊断和治疗Th2相关疾病中的用途 |
ITUB20155097A1 (it) * | 2015-11-05 | 2017-05-05 | Biouniversa Srl | Anticorpi umanizzati anti-BAG3 |
JP2019527535A (ja) * | 2016-05-18 | 2019-10-03 | 上海開拓者生物医薬有限公司Shanghai Pharmaexplorer Co., Ltd. | Il−13抗体およびその製造方法と使用 |
AU2017321682A1 (en) | 2016-09-01 | 2019-04-11 | Regeneron Pharmaceuticals, Inc. | Methods for preventing or treating allergy by administering an IL-4R antagonist |
TW202332696A (zh) | 2016-12-01 | 2023-08-16 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
WO2018106931A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
WO2018183932A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor |
WO2019028367A1 (en) | 2017-08-04 | 2019-02-07 | Regeneron Pharmaceuticals, Inc. | METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES |
PT3515465T (pt) | 2017-08-18 | 2024-03-04 | Regeneron Pharma | Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r |
US11034768B2 (en) | 2017-10-30 | 2021-06-15 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an IL-4R antagonist |
KR20220098056A (ko) | 2018-02-09 | 2022-07-08 | 제넨테크, 인크. | 비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법 |
CA3099066A1 (en) | 2018-05-13 | 2019-11-21 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r inhibitor |
WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
WO2020106757A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
CA3120578A1 (en) * | 2018-12-03 | 2020-06-11 | Dermata Therapeutics, Llc | Compositions for the treatment of conditions |
AU2020231343A1 (en) | 2019-03-06 | 2021-10-21 | Regeneron Pharmaceuticals, Inc. | IL-4/IL-13 pathway inhibitors for enhanced efficacy in treating cancer |
SG11202109002XA (en) | 2019-03-21 | 2021-09-29 | Regeneron Pharma | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
AU2020325021A1 (en) | 2019-08-05 | 2022-01-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist |
EP3870261B1 (en) | 2019-12-13 | 2024-01-31 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
WO2023130010A1 (en) | 2021-12-30 | 2023-07-06 | Regeneron Pharmaceuticals, Inc. | Methods for attenuating atopic march by administering an il-4/il-13 antagonist |
EP4227321A1 (en) * | 2022-02-10 | 2023-08-16 | AVA Lifescience GmbH | Antibodies targeting the b-cell receptor of chronic lymphocytic leukemia (cll) for use in treatment of cll |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US6051231A (en) * | 1988-09-01 | 2000-04-18 | Bayer Corporation | Antiviral methods and prepations |
ES2052027T5 (es) | 1988-11-11 | 2005-04-16 | Medical Research Council | Clonacion de secuencias de dominio variable de inmunoglobulina. |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
SK285960B6 (sk) | 1991-07-25 | 2007-12-06 | Biogen Idec Inc. | Rekombinantné protilátky na liečenie ľudí |
AU665025B2 (en) | 1991-09-23 | 1995-12-14 | Cambridge Antibody Technology Limited | Production of chimeric antibodies - a combinatorial approach |
GB9122820D0 (en) | 1991-10-28 | 1991-12-11 | Wellcome Found | Stabilised antibodies |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
GB9127376D0 (en) | 1991-12-24 | 1992-02-19 | Wellcome Found | Amidino derivatives |
GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
EP0633776B1 (en) | 1992-04-02 | 2001-05-09 | Smithkline Beecham Corporation | Compounds useful for treating allergic and inflammatory diseases |
EP0656064B1 (en) | 1992-08-17 | 1997-03-05 | Genentech, Inc. | Bispecific immunoadhesins |
ES2108460T3 (es) | 1993-06-03 | 1997-12-16 | Therapeutic Antibodies Inc | Fragmentos de anticuerpos en terapeutica. |
US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
NZ289157A (en) | 1994-06-15 | 1998-03-25 | Wellcome Found | Amidino sulphoxides and sulphones; medicaments for selective inhibition of inducible nitric oxide synthase |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
MY117948A (en) | 1997-01-13 | 2004-08-30 | Glaxo Group Ltd | Nitride oxide synthase inhibitors. |
DE19723722A1 (de) | 1997-05-30 | 1998-12-10 | Schering Ag | Nichtsteroidale Gestagene |
AU9281298A (en) | 1997-10-01 | 1999-04-23 | Kyowa Hakko Kogyo Co. Ltd. | Benzodioxole derivatives |
US6506766B1 (en) | 1998-02-13 | 2003-01-14 | Abbott Laboratories | Glucocortiocoid-selective antinflammatory agents |
US6255303B1 (en) | 1998-03-14 | 2001-07-03 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Phthalazinone PDE III/IV inhibitors |
GB9806530D0 (en) | 1998-03-26 | 1998-05-27 | Glaxo Group Ltd | Inflammatory mediator |
ES2230848T3 (es) | 1998-04-28 | 2005-05-01 | Smithkline Beecham Corporation | Anticuerpos monoclonales con inmunogenicidad reducida. |
GB9811599D0 (en) | 1998-05-30 | 1998-07-29 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
AU2750800A (en) * | 1999-02-01 | 2000-08-18 | Amgen Canada Inc. | Materials and methods to inhibit hodgkin and reed sternberg cell growth |
CN1353717A (zh) | 1999-05-04 | 2002-06-12 | 莱加制药公司 | 四环黄体酮受体调节剂化合物及其方法 |
ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
US6263209B1 (en) | 1999-07-28 | 2001-07-17 | Motorola, Inc. | Method and apparatus in a wireless communication system for creating a learning function |
CO5180649A1 (es) | 1999-09-01 | 2002-07-30 | Abbott Lab | Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes |
CZ20031195A3 (cs) | 2000-09-29 | 2003-09-17 | Glaxo Group Limited | Morfolinacetamidové deriváty |
GB0031179D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
US6484903B2 (en) | 2001-01-09 | 2002-11-26 | Riverwood International Corporation | Carton with an improved dispensing feature in combination with a unique handle |
GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
GB0105360D0 (en) | 2001-03-03 | 2001-04-18 | Glaxo Group Ltd | Chimaeric immunogens |
US7144908B2 (en) | 2001-03-08 | 2006-12-05 | Glaxo Group Limited | Agonists of beta-adrenoceptors |
DE60224172T2 (de) | 2001-03-22 | 2008-12-04 | Glaxo Group Ltd., Greenford | Formanilid-derivative als beta2-adrenorezeptor-agonisten |
BRPI0212455B8 (pt) | 2001-09-14 | 2021-05-25 | Glaxo Group Ltd | composto derivado de fenetanolamina para o tratamento de doenças respiratórias, formulação farmacêutica, combinação, e, uso do mesmo |
CN1555548A (zh) * | 2001-09-20 | 2004-12-15 | 先锋株式会社 | 发光元件驱动电路 |
US6960581B2 (en) | 2002-01-14 | 2005-11-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof |
AU2003214879B2 (en) | 2002-01-22 | 2008-02-07 | The Regents Of The University Of California | Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof |
GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
MXPA04009329A (es) | 2002-03-26 | 2005-01-25 | Boehringer Ingelheim Pharma | Mimeticos de glucocorticoides, metodos para su preparacion, composiciones farmaceuticas y usos de los mismos. |
EP1490317A1 (en) | 2002-03-26 | 2004-12-29 | Boehringer Ingelheim Pharmaceuticals Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
DE10215316C1 (de) | 2002-04-02 | 2003-12-18 | Schering Ag | Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer |
WO2003086451A1 (en) * | 2002-04-05 | 2003-10-23 | Centocor, Inc. | Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses |
WO2003086294A2 (en) | 2002-04-11 | 2003-10-23 | Merck & Co., Inc. | 1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators |
WO2003092610A2 (en) * | 2002-05-01 | 2003-11-13 | Regeneron Pharmaceuticals, Inc. | Methods of using cytokine antagonists to treat hiv infection and aids |
US7186864B2 (en) | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
US7074806B2 (en) | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
DK1521733T3 (da) | 2002-07-08 | 2014-10-13 | Pfizer Prod Inc | Modulatorer af glucocorticoid receptoren |
GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
WO2004009016A2 (en) | 2002-07-18 | 2004-01-29 | Bristol-Myers Squibb Company | Compositions and methods involving nuclear hormone receptor site ii |
WO2004009017A2 (en) | 2002-07-18 | 2004-01-29 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor and method |
KR20110027851A (ko) * | 2002-07-19 | 2011-03-16 | 애보트 바이오테크놀로지 리미티드 | TNFα 관련 질환의 치료 |
CA2496175A1 (en) | 2002-08-21 | 2004-03-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
JP2006503108A (ja) | 2002-09-16 | 2006-01-26 | グラクソ グループ リミテッド | ピラゾロ[3,4−b]ピリジン化合物およびそれのホスホジエステラーゼ阻害薬としての使用 |
CA2499150A1 (en) | 2002-09-20 | 2004-04-01 | Merck & Co., Inc. | Octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators |
GB0407315D0 (en) * | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
US7790405B2 (en) * | 2004-04-26 | 2010-09-07 | Centocor, Inc. | Solution phase biopanning method using engineered decoy proteins |
US7501121B2 (en) * | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
AR049390A1 (es) * | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
-
2005
- 2005-06-29 TW TW094121993A patent/TWI307630B/zh not_active IP Right Cessation
- 2005-06-30 AU AU2005259025A patent/AU2005259025B2/en not_active Ceased
- 2005-06-30 EP EP11181891.0A patent/EP2436697B1/en not_active Revoked
- 2005-06-30 EP EP05757024A patent/EP1802658B1/en active Active
- 2005-06-30 PE PE2005000762A patent/PE20060376A1/es not_active Application Discontinuation
- 2005-06-30 PT PT05757024T patent/PT1802658E/pt unknown
- 2005-06-30 RU RU2007103826/10A patent/RU2404192C2/ru not_active IP Right Cessation
- 2005-06-30 WO PCT/GB2005/002581 patent/WO2006003407A2/en active Application Filing
- 2005-06-30 US US11/570,736 patent/US7807788B2/en not_active Expired - Fee Related
- 2005-06-30 PL PL05757024T patent/PL1802658T3/pl unknown
- 2005-06-30 AR ARP050102731A patent/AR049565A1/es unknown
- 2005-06-30 DK DK05757024.4T patent/DK1802658T3/da active
- 2005-06-30 ES ES05757024T patent/ES2378173T3/es active Active
- 2005-06-30 BR BRPI0512826-9A patent/BRPI0512826A/pt not_active IP Right Cessation
- 2005-06-30 AT AT05757024T patent/ATE535545T1/de active
- 2005-06-30 KR KR1020077002166A patent/KR20070034609A/ko active IP Right Grant
- 2005-06-30 CA CA002571799A patent/CA2571799A1/en not_active Abandoned
- 2005-06-30 NZ NZ552063A patent/NZ552063A/en not_active IP Right Cessation
- 2005-06-30 SI SI200531473T patent/SI1802658T1/sl unknown
- 2005-06-30 ES ES11181891.0T patent/ES2456897T3/es active Active
- 2005-06-30 JP JP2007518695A patent/JP5102616B2/ja not_active Expired - Fee Related
- 2005-06-30 MX MX2007000026A patent/MX2007000026A/es active IP Right Grant
- 2005-06-30 SG SG200904563-4A patent/SG153878A1/en unknown
-
2006
- 2006-12-18 IL IL180152A patent/IL180152A0/en unknown
- 2006-12-29 MA MA29577A patent/MA28726B1/fr unknown
-
2007
- 2007-01-11 NO NO20070189A patent/NO20070189L/no not_active Application Discontinuation
-
2010
- 2010-08-24 US US12/862,235 patent/US20110243928A1/en not_active Abandoned
-
2012
- 2012-02-10 HR HR20120139T patent/HRP20120139T1/hr unknown
- 2012-02-21 CY CY20121100172T patent/CY1112372T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL1802658T3 (pl) | Chimeryczne i humanizowane przeciwciała monoklonalne przeciw interleukinie-13 | |
IL272883A (en) | Monoclonal antibodies and their uses | |
HK1098825A1 (en) | Human monoclonal antibodies against cd20 | |
IL190502A0 (en) | Anti-addl monoclonal antibody and use thereof | |
IL176755A0 (en) | M-csf-specific monoclonal antibody and uses thereof | |
IL179672A (en) | Monoclonal antibodies against 3 cd human | |
EP1717250A4 (en) | MONOCLONAL ANTIBODY AND ITS USE | |
ZA200805526B (en) | Chimeric and humanised anti-human IL-13 antibodies | |
IL191217A (en) | Anti-17 mantle monoclonal antibody | |
IL206709A0 (en) | Il-31 monoclonal antibodies | |
IL187710A0 (en) | Anti-trkb monoclonal antibodies and uses thereof | |
IL184152A0 (en) | Monoclonal antibodies against nkg2a | |
HK1078589A1 (en) | Anti-human tenascin monoclonal antibody | |
EP1940466A4 (en) | ANTI-ADDL MONOCLONAL ANTIBODIES AND THEIR USE | |
IL181625A0 (en) | Humanized anti-5t4 antibodies and anti-5t4 antibody/calicheamicin conjugates | |
EP1718749A4 (en) | ANTI-AF-20 HUMANIZED MONOCLONAL ANTIBODY | |
HK1100848A1 (en) | Anti-human tenascin monoclonal antibody | |
ZA200706185B (en) | Monoclonal antibodies against NKG2A | |
SI1899377T1 (sl) | Humanizirana protitelesa, specifična za NOGO-A, in njihove farmacevtske uporabe | |
EP1820855A4 (en) | MONOCLONAL ANTI-HISTON-H1 ANTIBODY AND ITS MANUFACTURE OF HYBRIDOMA | |
EP1712564A4 (en) | MONOCLONAL ANTIBODY ANTI-NC1 | |
GB0415644D0 (en) | Monoclonal antibody | |
IL165753A0 (en) | Humanized monoclonal antibody nPAM4 | |
EP1944323A4 (en) | NEW MONOCLONAL ANTIBODY AND APPLICATION THEREOF |